Joseph A. Sliman
Public Health and Preventive Medicine
1 Medimmune Way
Gaithersburg, MD 20878
Gaithersburg, MD 20878
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Journal: The Lancet. Infectious diseases
Published: August 08, 2018
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Journal: Antimicrobial agents and chemotherapy
Published: October 14, 2016
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Journal: Clinical drug investigation
Published: June 11, 2016
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Journal: Anaerobe
Published: January 14, 2016
Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
Journal: Alimentary pharmacology & therapeutics
Published: September 08, 2015
Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
Journal: Influenza and other respiratory viruses
Published: October 16, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026